-
2023-505842-24-00
5
2024-05-07
Moderate to Severe Plaque Psoriasis
-
2023-507640-36-00
5
2024-04-29
Resistant hypertension (rHTN) defined as blood pressure that remains h
-
2022-502899-23-00
5
2024-04-23
Hepatic Encephalopathy (OHE)
-
2023-506425-12-00
5
2024-04-17
Uncontrolled and Resistant Hypertension
-
2024-519625-38-00
5
2024-04-14
Postoperative pain relief
-
2023-506084-34-00
5
2024-04-12
Type 2 Diabetes
-
2023-505414-15-00
4
2024-04-10
Dermatitis, Atopic
-
2022-501421-20-00
5
2024-04-09
Gout with hyperuricemia
-
2023-506787-13-00
5
2024-04-03
Cessation of smoking
-
2023-506701-18-00
3
2024-03-27
No therapeutic indication in the current trial with healthy volunteers
-
2023-507300-30-00
3
2024-03-27
This study is a phase I trial to investigate the effect of inhibition
-
2023-503785-22-00
5
2024-03-25
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
-
2023-504678-39-00
4
2024-03-13
Heart Failure
-
2023-505499-32-00
5
2024-03-08
Uncontrolled hypertension (uTHN) defined as blood pressure that remain
-
2023-508656-19-00
2
2024-03-01
No therapeutic indication in the current trial with healthy volunteers
-
2022-501946-31-00
5
2024-02-29
Functional Constipation
-
2023-505543-39-00
5
2024-02-12
Chronic Obstructive Pulmonary Disease (COPD)
-
2022-501310-57-00
4
2024-02-05
Endometriosis related pain
-
2023-503333-22-00
5
2024-01-15
Moderate to severe controlled asthma according to Step 4 and Step 5 of
-
2023-503790-37-00
5
2024-01-09
Post-Menopausal Osteoporosis
-
2023-503315-15-00
4
2023-12-20
Thrombolysis of symptomatic proximal vein thrombosis
-
2022-501947-34-00
4
2023-12-05
Functional Constipation (FC)
-
2022-502854-16-00
4
2023-11-26
Asthma
-
2022-502208-64-00
4
2023-11-25
Asthma